Quick Answer
BioAtla, Inc. reported R&D Expense of $43.57 million for fiscal year 2025.
BioAtla, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $43.57M | -30.9% |
| 2024 | $63.09M | -39.2% |
| 2023 | $103.73M | +30.7% |
| 2022 | $79.35M | +36.2% |
| 2021 | $58.27M | +192.3% |
| 2020 | $19.93M | -23.1% |
| 2019 | $25.92M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.54M | -41.8% | -30.3% |
| June 30, 2025 | $13.68M | -15.5% | +10.8% |
| March 31, 2025 | $12.36M | -34.5% | -24.6% |
| September 30, 2024 | $16.39M | -42.3% | +1.2% |
| June 30, 2024 | $16.20M | -47.7% | -14.1% |
| March 31, 2024 | $18.85M | -13.1% | -33.6% |
| September 30, 2023 | $28.40M | +43.2% | -8.3% |
| June 30, 2023 | $30.96M | +49.5% | +42.7% |
- BioAtla, Inc. showed a decrease of -30.9% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, BioAtla, Inc.’s r&d expense has grown by 68.1% (from $25.92 million to $43.57 million).
- The most recent figure is from BioAtla, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: